Ever fix one slide and watch the agent regenerate the whole deck and break everything? This work solves that with hierarchical memory plus local revision 🗂️ Title: MemSlides: A Hierarchical Memory Driven Agent Framework for Personalized Slide Generation with Multi-turn Local Revision URL: ❓ What's new? 💡 It gives a slide-generation agent a hierarchical memory that cleanly separates persistent preferences (user profile), session-level working memory, and reusable tool experience. It also edits only the target slides instead of regenerating the full deck. ❓ How does it keep local edits from drifting? 💡 A Plan–Act–Guard loop. Plan turns a request into an explicit "execution contract" (target paths, active rules, coverage requirements); Act picks tools like batch CSS over shared selectors or patch operations; Guard binds patches to content hashes and blocks premature finalization until all targets are covered. ❓ Do one-off instructions leak into permanent preferences? 💡 No — at job end, intent-aware consolidation writes back only stable signals, preventing transient "just this round" requests from becoming persistent preferences. ❓ Does it work? 💡 In blind review, personalization beats DeepPresenter on every dimension (e.g. Visual +1.66). With tool memory, closed-loop completion hits 0.963 and time-to-first-correct-edit drops 609.5s → 242.5s (~60% faster). Designing agent memory by role rather than one flat store feels broadly useful for multi-turn editing tasks. #AIAgents# #LLM#

Introducing Higgsfield Layers. Our image editor with layer decomposition, flawless text rendering, and native 4K. > Upload or generate any image > Split it into layers and edit each separately > Regenerate any text or object without changing the whole image

Researchers at MIT have developed an innovative injectable gel capable of regrowing damaged nerves, successfully restoring sensation in affected areas. Nerve injuries, which often result from trauma, surgery, or disease, can lead to long-term loss of feeling, motor control, and quality of life. This breakthrough offers a potential solution for patients suffering from nerve damage that previously had limited treatment options. The gel works by providing a supportive scaffold that encourages nerve cells to regenerate and reconnect with their target tissues. Bioactive compounds within the gel stimulate cellular repair, guiding nerve fibers to grow in the correct direction and restoring communication between the nervous system and affected body parts. Preclinical studies demonstrated that treated nerves recovered structure and function, leading to full restoration of sensation. Unlike traditional treatments, which often rely on surgery or prosthetics, this injectable approach is minimally invasive and targets the root cause of nerve dysfunction. Researchers believe it could revolutionize treatment for peripheral nerve injuries, spinal cord damage, and other neuropathies. Ongoing studies aim to optimize the gel’s formulation, assess long-term safety, and prepare for human clinical trials. If successfully translated to clinical use, this therapy could dramatically improve outcomes for patients, restoring both sensation and functionality and reducing chronic pain associated with nerve damage. This research highlights the growing power of regenerative medicine, demonstrating how engineered biomaterials can repair complex tissue structures and restore lost biological function.

I'm a cardiologist. Every day I tell patients some version of the same hard truth: the heart muscle you lost in your heart attack is gone. It won't grow back. We can open the artery, but the dead zone becomes scar — and scar doesn't beat. A 25-year-old scientist in Argentina is trying to prove me wrong. And her approach is clever enough that I'm rooting for her. Here's the problem she's attacking. When an artery blocks, heart muscle in that zone starts dying within hours. Unlike your skin or your liver, the adult human heart barely regenerates. So your body does the only thing it can — it patches the hole with fibrous scar. That scar doesn't contract. The heart pumps weaker, stretches, thins, and marches toward heart failure. This is why roughly half of heart failure patients die within five years. We manage the decline. We don't reverse it. Pilar Ferrer and her team at Amnova Biotech are going after the thing we've never solved: rebuilding the muscle itself. Their tool is inspired by one of the most quietly remarkable tissues in biology — the amniotic membrane. The sac that surrounds a baby in the womb. It's rich in regenerative and anti-inflammatory factors, and doctors already use it to heal stubborn wounds and repair the cornea. They've turned that biology into an injectable hydrogel. Cell-free — no stem cells, no animal components. It ships as a room-temperature powder, gets reconstituted, and is injected directly into the damaged heart zone, ideally during bypass surgery — the operation another Argentine, René Favaloro, gave the world. Once inside, it acts as a temporary scaffold that reengineers the healing environment: it calms the destructive inflammation, grows new blood vessels, and signals the heart's own cells to proliferate and repopulate the dead zone. Instead of surrendering to scar, the tissue gets a second chance to rebuild. The early data, in sheep — chosen because their hearts are close to ours in size and physiology — showed at 28 days: smaller infarcts, improved heart function, more new blood vessels, more dividing cardiac cells. Now the honest part, because I owe you both halves. This is early. It's preclinical. And the history of cardiology is a graveyard of therapies that looked beautiful in sheep and pigs and then failed in humans — different immune responses, different healing, different scale. Human trials aren't expected until around 2028. There is no peer-reviewed efficacy publication yet. This is a candidate to watch, not a treatment to expect. But I want to tell you why it still moves me. The whole strategy is elegant. It doesn't fight the body — it borrows the body's own oldest regenerative wisdom, the biology that builds an entire human being from scratch, and points it at a broken heart. It's cell-free, so it sidesteps the rejection and manufacturing nightmares that have stalled stem-cell approaches. It's stable at room temperature and delivered during an operation we already perform. Practical, not sci-fi. And it's the frontier I've been writing about for months, arriving from an unexpected place: the shift from managing damage to reversing it. Gene editing for cholesterol. Cell therapy for diabetes. Enzymes that erase arterial aging. And now, maybe, a gel that teaches the heart to remember how to heal. For my entire career, "the muscle is gone" has been a sentence with no appeal. A 25-year-old may be writing the appeal. Science with an Argentine accent — born in the same country that gave the world the bypass. Worth watching closely.

A 25-year-old scientist is taking on one of cardiology's biggest challenges: helping the heart repair itself after a heart attack. When a heart attack blocks blood flow, heart muscle cells in the affected area can die within hours. Unlike tissues such as the skin or liver, the heart has very little ability to regenerate. Instead, the damaged area is replaced with scar tissue, which can't contract like healthy muscle. Over time, this loss of function can weaken the heart and increase the risk of chronic heart failure. Pilar Ferrer, a biologist and graduate of Favaloro University in Argentina, is developing an experimental hydrogel through her startup, Amnova Biotech. Inspired by the amniotic membrane—a placental tissue already used in regenerative medicine—the gel is designed to be injected into damaged heart tissue, where it serves as a supportive scaffold that may encourage the body's own repair processes rather than leaving behind only scar tissue. So far, studies in sheep have shown encouraging results, including smaller areas of damage and improved heart function after treatment. While these findings are exciting, they're still in the early stages. Human clinical trials are not expected to begin until around 2028, and many therapies that succeed in animals ultimately fail to produce the same results in people. If future research confirms its effectiveness, this regenerative strategy could represent a major shift in how heart attack damage is treated. Would you be interested in seeing treatments that focus on rebuilding heart tissue instead of simply managing permanent scarring?

Regarding claims about Shri Avaneesh Srivastava (App No. 260411198880, Roll No. 2001805051) and his NEET (UG) 2026 OMR answer sheet: NTA has verified the record. The genuine OMR of the candidate is on file. It was also emailed to him at the registered e-mail address during the OMR Response Key challenge window. It bears the candidate’s correct name (Avaneesh Srivastava), the name of his father (Mukesh Kumar) and the name of his mother (Rekha Kumari), his signature and thumb impression, and the signatures of the invigilators. The image being circulated is not an OMR sheet issued by NTA. The identity inserted into that image ("Ajeet Singh, son of Shri Lakhan Singh and Smt. Reena Singh") does not correspond to any candidate registered for NEET (UG) 2026. No candidate by that name and parentage exists in the NEET (UG) 2026 database. The image is a digitally regenerated version of the candidate’s own genuine OMR sheet. The identity fields have been overwritten, and the printed portion of the sheet has been regenerated by AI or OCR-based tools, producing visible errors on portions of the genuine OMR sheet and cannot be altered by any candidate with a pen. The candidate’s own OMR sheet on record has been correctly evaluated. The score of 337 marks is verified and stands as declared. Creating or circulating a forged OMR answer sheet is an offence under the Public Examinations (Prevention of Unfair Means) Act, 2024. More details on the Public Notice dated 20 July 2026:

Linux builds of Cemu 2.6 were compromised with malware between May 6 and May 12, 2026. Affected files: - Cemu-2.6-x86_64.AppImage - cemu-2.6-ubuntu-22.04-x64zip >The malware could steal passwords, browser session tokens, SSH keys, GitHub credentials, cloud access tokens, and other sensitive authentication data. >The compromise originated from a stolen developer GitHub token used to replace official Linux release binaries on GitHub. >Windows, macOS, and Flatpak versions were unaffected. If you downloaded or executed the affected builds, take these steps: - Reinstall your operating system - Change passwords for important accounts - Revoke and regenerate SSH keys, GitHub tokens, API keys, and cloud credentials - Remove the compromised binaries - Review your system for unauthorized access